Will Rihanna Tete-A-Tete Crush Snap?
A few weeks ago pop star Rihanna and Snapchat (SNAP) made major headlines. Snapchat ran an advertisement for a game called "Would you rather."...
GE: Warren Buffett Is Barking Up The Wrong Tree
The U.S. financial markets have been on a sugar high over the past decade. I doubt dip buyers will want the ride to end....
Trump Threatens To Sue Opioid Drug Makers
President Donald Trump stepped up criticism of opioid drug manufacturers. He recently intimated he was considering suing drugmakers for their role in fueling the...
Valeant Is Insolvent
The wealth effect orchestrated by former Fed Chairman Ben Bernanke has helped send financial markets to record highs. The Dow Jones (DIA) was around...
Allergan, Mohawks Receive IPR Stay For Restasis
Wednesday market chatter suggested a Federal Circuit Court stayed an inter partes review ("IPR") pursuant to patents for Allergan's (AGN) dry eye drug Restasis....
Did Cambridge Analytica Debacle Kill Facebook’s Business Model?
Facebook (FB) has dominated the financial news cycle over the past weeks pursuant to its relationship with Cambridge Analytica, a political consulting firm with...
Is Mallinckrodt Exposed To Claims Of Fraudulent Conveyance?
Certain of Mallinckrodt's (MNK) key product segments are in disarray. Revenue from the Specialty Generics unit has been in free fall for several quarters....
Endo Pharmaceuticals: The Free Fall Continues
There is a war being fought over drug prices. Lawmakers have hit back at price gougers and opioid manufacturers, and Endo Pharmaceuticals (ENDP) is...
Leonard Hamilton Reacted To Dana Jacobson’s Troll Attempt With Aplomb
The Florida Sate Seminoles lost to the Michigan Wolverines in the Elite 8 Saturday night 58-54. The win sent Michigan to the NCAA Finals...
Gilead: Did Biktarvy Kill The Sell Thesis?
In February Gilead (GILD) received FDA approval for Biktarvy, a once daily single tablet regimen for the treatment of HIV:
Gilead Sciences, Inc. (NASDAQ:GILD) today...
